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Gastrointestinal stromal tumors (GISTs) compose the largest category of well-recognized nonepithelial neoplasms of the
gastrointestinal tract (GI). GISTs of the gallbladder are extremely rare tumors. Only four malignant, two benign and one GIST-
like tumor of the gall bladder have ever been described. The four malignant GISTs were all positive for CD 117 antigen (c-kit).
We present for the ﬁrst time a malignant gastrointestinal stromal tumor of the gallbladder, immunoreactive for platelet-derived
growth factor receptor alpha (PDGFRA) and negative for CD 117 antigen (c-KIT).
1.Introduction
Gastrointestinal stromal tumors (GISTs) are well recognized
nonepithelial neoplasms of the gastrointestinal tract (GI).
After decades of ultra structural, immunohistochemical, and
genetics tudies ,itisno wevidentthatm os tGIST sar ebeliev ed
to diﬀerentiate from Cajal (ICCs) pacemaker cells. The Cajal
pacemakercellsareinvolvedingastrointestinal tractmobility
and regulation of autonomous neuronal transmission [1].
The vast majority of GISTs arises in the stomach (50%).
Other common sites include the jejunum and ileum (30%),
duodenum(5%),colonandrectum(5%),andtheesophagus
(5%) [2]. Only seven gallbladder GISTs have ever been
reported, and of these, four were malignant [3–9]. These
malignant gallbladder GISTs were all positive for CD 117 (c-
kit) and CD34 or CD117 alone [4–7]. We report a unique
gallbladder GIST which is negative for CD 117 and CD 34
but positive for platelet-derived growth factor receptor alpha
(PDGFRA).Apartfromtheextremely rare siteofoccurrence,
GIST of the gallbladder remains a challenging topic and
needs to be examined on the basis of histologic ﬁndings,
clinical history, and molecular proﬁle with the later having
signiﬁcant impact on the treatment strategy.
2.Case Report
A 72-year-old woman was admitted to the First Department
of Surgery, University of Athens with symptoms suggestive
of obstructive jaundice: fever and chills, dark urine, inter-
mittent right upper quadrant (RUQ) abdominal pain, and
jaundice. Clinical examination revealed mild tenderness in
the RUQ only with no palpable masses. Initial investigations
showed a white cell count (WCC) of 11,556cells/mm3,T o t a l
Bilirubin/Direct Bilirubin (TBil/DBil) of 4.80/3.60mg/dL,
alkaline phosphatase (ALP) 440IU/L, and γ-glutamyl tran-
speptidase (γ-GTP) 210IU/L. Tumor markers were within
the normal range. Ultrasound demonstrated a thickened2 HPB Surgery
gallbladderwall,bilestones,andmoderatecommonbileduct
(CBD) dilatation. Bile duct lithiasis was suspected and an
endoscopic retrograde cholangiopancreatography (ERCP)
was performed. This demonstrated an almost complete
obstruction at the level of the cystic duct and common
hepatic duct conﬂuence. However, the underlying pathology
could not be identiﬁed, and an exploratory laparotomy was
decided. This revealed a large irregular hard mass at the site
of the gallbladder. The mass was adherent to the duodenum
involving the conﬂuence of the cystic duct with the common
hepatic duct and the retroduodenal part of the common
bile duct. Cholecystectomy was performed along with wedge
resection of the gallbladder bed. The common bile duct and
common hepatic were excised en bloc with the specimen
ensuring free surgical margins along the extrahepatic billiary
tree. Lymph node dissection was performed of the hepato-
duodenal ligament, the hepatic artery lymph nodes, and the
retropancreatic lymph nodes. The enteric-billiary continuity
was established through a retrocolic Roux-en-Y hepatico-
jejunostomy. The postoperative course was uneventful, and
the patient was discharged ten days after operation.
In the pathological review, the gallbladder was dilated
andmeasur ed7.5cm×3.5cminsize.Withinthegallbladder,
there was a wide mass covering the entire wall, neck, and
body,whiletheremainderofthemucosallayerwasulcerated.
Microscopically, tumor cells inﬁltrated the muscle layer were
spindle shaped in nature, arranged in a short fascicle pattern
and immunopositive for PDGFRA (Figures 1(a) and 1(b)).
The cells demonstrated hypercromatic nuclei, severe
pleomorphism and an increased mitotic rate of up to 50
mitosis/50 high power ﬁeld (HPF). The tumor exhibited
focal necrosis and was inﬁltrating into the pericystic adipose
tissue.
3.MutationalAnalysis ofc-Kitand PDGFRA
3.1. Material and Methods
Genomic DNA Isolation. Ten μm sections were cut from
the paraﬃn-embedded tissue block and treated with
xylene/ethanol. The samples were digested overnight at
37◦C using proteinase K. DNA was extracted with phenol-
chloroform, precipitated in ice-cold ethanol, redissolved in
distilled water, and quantitated using a Picodrop Microliter
spectrophotometer.
High-Resolution Melting Analysis. For the detection of c-
Kit exon 9, 11, 13, and 17 mutations as well as PDGFRA
mutations in exons 12 and 18, a real-time polymerase chain
reaction approach followed byhigh-resolution melting curve
analysis has proved to be a rapid, highly sensitive, and
eﬃcient screening method. Subsequently, sequencing of the
PCR products is applied for mutation identiﬁcation. PCR
and HRM were consecutively performed on a LightCycler
480 (Roche Diagnostics, GmbH, Germany) in one single
run, and all reactions were repeated twice. Each reaction
c o n s i s t e do f2 0 n go fD N A ,2 0 0 n m o l / Lo fe a c hp r i m e r ,
10μL of LightCycler LC480 High Resolution Melting Master
(a)
(b)
Figure 1:(a)Spindleshapedtumorcells arrangedinashortfascicle
pattern (HE staining ×200). (b) Tumor cells are diﬀusely immune-
positive for PDGFRA (×200).
(Roche), 3.5mM MgCl2 and PCR-grade water adjusted to a
total volume of 20μL.
Sequencing. PCR products with an abnormal HRM pat-
tern were sequenced using the Big Dye terminator cycle
sequencing kit (Applied Biosystems, California, USA). The
sequencing products were analysed on an ABI Prism 310
Genetic Analyzer (Applied Biosystems).
4.Results
The specimen was analysed for the presence of activating
mutations in exons 9, 11, 13, and 17 of c-Kit gene as well
as exons 12 and 18 of PDGFRA gene by performing High
Resolution Melting Analysis and Sequencing.
A mutation at codon 824 coding for valine in exon 18
of PDGFRA gene was detected by high-resolution melting
analysis (HRM) and was further conﬁrmed by sequencing
as c. 2472 C>T, p. V824V (Figure 2). This silent mutation
has previously been described in 2 tumors from the central
nervous system (gliosarcomas) as well as in soft-tissue
tumors (GISTs).HPB Surgery 3
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Figure 2: Electropherogram of part of PDGFRA sequence. DNA
sequencing of silent mutation as c. 2472 C>T, p. V824V.
No c-Kit mutations were found. Results were veriﬁed
by a second independent PCR reaction and HRM analysis
followed by sequencing.
5.Discussion
An estimated ﬁve-to-six thousand new cases of GIST are
diagnosed annually with 10% to 30% of these being peri-
toneum [2]. Most tumors are sporadic, aﬀecting individuals
in their 5th or 6th decade with some evidence indicating a
male predominance [2]. GISTs can also present earlier and
this is often seen in one of the rare “GIST syndromes”, which
include neuroﬁbromatosis type 1 (NF1), the Carney-Strat-
akis dyad and familial GIST syndrome [2]. These tumors
may occur anywhere in the gastrointestinal tract but most
commonly present in the stomach and small intestine. They
can also occur in the surrounding structures such as the per-
itoneum, omentum, liver, pancreas, ovaries, and uterus [2].
ManyGISTsareasymptomaticandarediscoveredincidental-
ly;however,overhalfofgastricGISTspresentwithsignsofGI
bleeding and anaemia with a smaller proportion presenting
with abdominal pain or as an abdominal mass [10].
GISTS are diagnosed based on the morphological and
immunohistological features. Histology can often be varied,
but GISTs are broadly divided into spindle, epithelioid, or
mixed cell types. In general, the risk of malignancy is greater
in epithelioid tumors than in spindle-celled neoplasms [11,
12]. With the adventofimmunohistology, the diﬀerentiation
of GIST from other mesenchymal tumours has been made
possible. Previously, sarcomas, undiﬀerentiated carcinomas,
and melanomas would have featured heavily in the diﬀeren-
tial diagnosis; however, these can largely be excluded with
identiﬁcation or absence of speciﬁc immunohistochemical
markers [13]. The three most well-described immunohis-
tochemical markers in GISTs are CD117 (c-Kit), PDGFRA,
and CD34 [13, 14] .K i ti sp o s i t i v ei no v e r9 5 %o fG I S T sa n d
only 5–8% of tumors are Kit negative and PDGFRA positive
[14]. CD34 is a less sensitve marker for GISTs but is reported
in up to 60–70% of the tumors [14]. Miettinen and Lasota
who have carried out the largest everstudies on GISTs deﬁne
these tumors as generally Kit-positive and Kit or PDGFRA
mutation-driven mesenchymal tumors of the GI tract with
a set of characteristic histologic features including spindle
cell, epithelioid, and rarely pleomorphic morphology [14].
We present the case of a malignant GIST of the
gallbladder which demonstrated spindle cell morphology
and was PDGFRA positive and Kit negative. There have
been a small number of gallbladder GISTs described in the
literature, of which only four were malignant and all were
Kit positive. To our knowledge this presents the ﬁrst ever
recorded presentation of such a GIST. The signiﬁcance of the
Kit negative genotype has implications on the response to
further management. The identiﬁcation of speciﬁc cellular
markers has led to the development of eﬀective targeted
agents, namely, tyrosine kinase inhibitor (TKI) therapy (e.g.,
imatinib). These have had dramatic eﬀects in prolonging
progression free survival in advanced unresectable disease
[15]. Most Kit positive tumors are sensitive to imatinib;
however, the majority (80%) of PDGFRA mutations are
resistant to treatment [16].
Primary GISTs, as in the case here, have the potential
for curative treatment with surgical resection. Overall 5-year
survival rates for resectable GISTs have been shown to range
from 46% to 78.5%; however, predicting the recurrence rate
of primary resectable GISTs has been very challenging [17,
18]. The survival rates from the reported gall bladder GISTs
are mixed with only short-term followup noted in some of
the cases. Although the mutation status is important, the
current most important prognostic factor for GISTs is tumor
size, mitotic count, and tumor location [19]. This scheme
has evolved from studies initially outlined by the National
Institute of Health (NIH) and were greatly expanded on by
the work of Miettinen and Lasota [13, 14]. The patient in
this case had a very large tumor, with 50 mitosis/50 HPF,and
was located in the gallbladder. The ﬁrst two ﬁndings alone
place this GIST in the high-risk group for recurrence. This
is likely compounded by the Kit negative immunohistology
which would potentially reduce the beneﬁt of tyrosine
kinase inhibitors treatment. It is important to mention that
the immunohistochemical examination does not provide
information on the exon aﬀected on the type of mutation
both of which may be prognostically important.
6.Conclusion
This paper, presents a very unique case of GIST, located in
the gallbladder, negative for Kit, and positive for PDGFRA.
Apart from this being a previously undocumented case, it
highlights the challenges in establishing the diagnosis, prog-
nosis, and most eﬀective management for this unpredictable
tumour.
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